-
Something wrong with this record ?
A comparison of heart failure patients with reduced ejection fraction in the Moravian Midlands Registry with the LCZ696 patients in the Paradigm-HF trial
L. Pavlu, M. Vicha, J. Flasik, J. Petrkova, M. Taborsky, T. Kacirkova, O. Holy
Language English Country Czech Republic
Document type Journal Article, Comparative Study, Multicenter Study, Randomized Controlled Trial
NLK
Directory of Open Access Journals
from 2001
Free Medical Journals
from 1998
Medline Complete (EBSCOhost)
from 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
from 2001
PubMed
36748670
DOI
10.5507/bp.2023.006
Knihovny.cz E-resources
- MeSH
- Aminobutyrates * therapeutic use MeSH
- Angiotensin Receptor Antagonists * therapeutic use MeSH
- Biphenyl Compounds * therapeutic use MeSH
- Drug Combinations * MeSH
- Middle Aged MeSH
- Humans MeSH
- Natriuretic Peptide, Brain blood MeSH
- Registries * MeSH
- Retrospective Studies MeSH
- Aged MeSH
- Heart Failure * drug therapy physiopathology MeSH
- Stroke Volume * physiology MeSH
- Tetrazoles therapeutic use MeSH
- Valsartan * therapeutic use MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Randomized Controlled Trial MeSH
- Comparative Study MeSH
- Geographicals
- Czech Republic MeSH
BACKGROUND AND AIMS: There are limited data on real clinical practice in heart failure patients in the Czech Republic. We analysed the clinical parameters from the Moravian Midlands Registry (MMR) and compared them to LCZ696 patients in the Paradigm-HF trial. The Moravian Midlands Registry is a retrospective patient database from two outpatient cardiology centres in the Czech Republic. The Paradigm-HF is a large-scale prospective randomized multicentre trial with more than 8000 individuals with stabilized chronic heart failure. METHODS: A retrospective analysis of heart failure with reduced ejection fraction patients from two outpatient cardiology centres in the Czech Republic from October 2016 to December 2019. RESULTS: Patients in the MMR were younger (60.5 ± 10.7 vs 63.8 ± 11.5 years, P<0.05), had a higher body mass index (30.3 ± 5.0 vs 28.1 ± 5.5, P<0.05) and higher serum creatinine level (101.9 ± 36.0 vs 99.9 ± 26.5 μmol/L, P<0.05). MMR patients had lower left ventricular ejection fraction (27.8 ± 6.9 vs 29.6 ± 6.1%, P<0.05). The serum N-terminal pro-B-type natriuretic peptide, [2563.5 (377-3536) vs 1631 (885-3154), was non significantly higher P=0.07]. Pharmacotherapy use differed for mineralocorticoid antagonist (91.4% in MMR vs 54.2% in Paradigm-HF), and digoxin (13.5% vs 29.2%). Beta-blocker use was similar (96.2% vs 93.1%) as was angiotensin-converting enzyme (ACE) inhibitors - (71.2% vs 78.0%) and angiotensin-receptor blockers - ARB (27.9% vs 22.2%). Dosages of the commonly used ACE inhibitors at the screening visit (Paradigm-HF) / before angiotensin receptor-neprilysin inhibitor administration (MMR) differed significantly only for ramipril (7.0 ± 3.1 mg vs 4.8 ± 2.9 mg, P<0.05), dosages of ARB were - losartan (67.1 ± 30.2 vs 39.6 ± 32.0 mg, P=0.09) and valsartan (181.5 ± 71.1 vs 130.9 ± 82.2 mg, P=0.07). There was a substantial difference in device-based therapy (ICD in 60.6%, CRT 25.9% in MMR vs 14.9% and 7.0% in Paradigm-HF). CONCLUSION: The differences between the groups for the majority of clinical parameters compared were minimal, except for younger age, higher body mass index and serum creatinine level and lower left ventricular ejection fraction and substantially lower dosage of administered ramipril prior to commencing sacubitril/valsartan therapy. There was a higher prevalence of implantable cardioverter-defibrillators (ICD) and cardiac resynchronization therapy (CRT) in the MMR group.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24017565
- 003
- CZ-PrNML
- 005
- 20250527095255.0
- 007
- ta
- 008
- 241004s2024 xr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2023.006 $2 doi
- 035 __
- $a (PubMed)36748670
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Pavlů, Luděk $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czech Republic $7 xx0236019
- 245 12
- $a A comparison of heart failure patients with reduced ejection fraction in the Moravian Midlands Registry with the LCZ696 patients in the Paradigm-HF trial / $c L. Pavlu, M. Vicha, J. Flasik, J. Petrkova, M. Taborsky, T. Kacirkova, O. Holy
- 520 9_
- $a BACKGROUND AND AIMS: There are limited data on real clinical practice in heart failure patients in the Czech Republic. We analysed the clinical parameters from the Moravian Midlands Registry (MMR) and compared them to LCZ696 patients in the Paradigm-HF trial. The Moravian Midlands Registry is a retrospective patient database from two outpatient cardiology centres in the Czech Republic. The Paradigm-HF is a large-scale prospective randomized multicentre trial with more than 8000 individuals with stabilized chronic heart failure. METHODS: A retrospective analysis of heart failure with reduced ejection fraction patients from two outpatient cardiology centres in the Czech Republic from October 2016 to December 2019. RESULTS: Patients in the MMR were younger (60.5 ± 10.7 vs 63.8 ± 11.5 years, P<0.05), had a higher body mass index (30.3 ± 5.0 vs 28.1 ± 5.5, P<0.05) and higher serum creatinine level (101.9 ± 36.0 vs 99.9 ± 26.5 μmol/L, P<0.05). MMR patients had lower left ventricular ejection fraction (27.8 ± 6.9 vs 29.6 ± 6.1%, P<0.05). The serum N-terminal pro-B-type natriuretic peptide, [2563.5 (377-3536) vs 1631 (885-3154), was non significantly higher P=0.07]. Pharmacotherapy use differed for mineralocorticoid antagonist (91.4% in MMR vs 54.2% in Paradigm-HF), and digoxin (13.5% vs 29.2%). Beta-blocker use was similar (96.2% vs 93.1%) as was angiotensin-converting enzyme (ACE) inhibitors - (71.2% vs 78.0%) and angiotensin-receptor blockers - ARB (27.9% vs 22.2%). Dosages of the commonly used ACE inhibitors at the screening visit (Paradigm-HF) / before angiotensin receptor-neprilysin inhibitor administration (MMR) differed significantly only for ramipril (7.0 ± 3.1 mg vs 4.8 ± 2.9 mg, P<0.05), dosages of ARB were - losartan (67.1 ± 30.2 vs 39.6 ± 32.0 mg, P=0.09) and valsartan (181.5 ± 71.1 vs 130.9 ± 82.2 mg, P=0.07). There was a substantial difference in device-based therapy (ICD in 60.6%, CRT 25.9% in MMR vs 14.9% and 7.0% in Paradigm-HF). CONCLUSION: The differences between the groups for the majority of clinical parameters compared were minimal, except for younger age, higher body mass index and serum creatinine level and lower left ventricular ejection fraction and substantially lower dosage of administered ramipril prior to commencing sacubitril/valsartan therapy. There was a higher prevalence of implantable cardioverter-defibrillators (ICD) and cardiac resynchronization therapy (CRT) in the MMR group.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a srdeční selhání $x farmakoterapie $x patofyziologie $7 D006333
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a valsartan $x terapeutické užití $7 D000068756
- 650 12
- $a tepový objem $x fyziologie $7 D013318
- 650 12
- $a registrace $7 D012042
- 650 12
- $a bifenylové sloučeniny $x terapeutické užití $7 D001713
- 650 12
- $a aminobutyráty $x terapeutické užití $7 D000613
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a fixní kombinace léků $7 D004338
- 650 12
- $a antagonisté receptorů pro angiotenzin $x terapeutické užití $7 D057911
- 650 _2
- $a tetrazoly $x terapeutické užití $7 D013777
- 650 _2
- $a natriuretický peptid typu B $x krev $7 D020097
- 651 _2
- $a Česká republika $x epidemiologie $7 D018153
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Vícha, Marek $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czech Republic $7 xx0229304
- 700 1_
- $a Flašík, Jakub $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czech Republic $7 xx0271081
- 700 1_
- $a Petřková, Jana $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czech Republic $u Department of Pathological Physiology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic $7 xx0117676
- 700 1_
- $a Táborský, Miloš, $d 1962- $u Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Olomouc, Czech Republic $7 jn20010310074
- 700 1_
- $a Schovánková, Tereza $u Science and Research Centre, Faculty of Health Sciences, Palacky University Olomouc, Olomouc, Czech Republic $7 xx0331955
- 700 1_
- $a Holý, Ondřej $u Science and Research Centre, Faculty of Health Sciences, Palacky University Olomouc, Olomouc, Czech Republic $7 xx0222173
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1804-7521 $g Roč. 168, č. 3 (2024), s. 229-234
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36748670 $y Pubmed
- 910 __
- $a ABA008 $b A 1502 $c 958 $y p $z 0
- 990 __
- $a 20241004 $b ABA008
- 991 __
- $a 20250527095255 $b ABA008
- 999 __
- $a ok $b bmc $g 2316485 $s 1229515
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 168 $c 3 $d 229-234 $e 20230206 $i 1804-7521 $m Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $n Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub $x MED00012606
- LZP __
- $b NLK124 $a Pubmed-20241004